Fundraising Fox

Arvelle Therapeutics

Zug, CH · 4 known investors

Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals. Its Swiss portfolio includes the antiepileptic medication Ontozry (cenobamate).

BiotechConsumerHealthtech

Investors · 4

Andera PartnersParis
F-Prime CapitalCambridge · $3M – $10M
H.I.G. CapitalMiami
H.I.G. HealthBridge PartnersMiami · $5M – $40M

In the news

Arvelle Therapeutics raises $180m in Series A financing - European Biotechnology Magazineeuropean-biotechnology.com · Feb 2019Axovant sends off its small molecule team with an epilepsy drug and $100M in funding commitments | Fierce Biotechfiercebiotech.com · Feb 2019Italy’s healthcare group Angelini buys Swiss-based Arvelle in $1 billion deal | NovaQuest Capital Managementnovaquest.com

Frequently asked questions

What does Arvelle Therapeutics do?
Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals. Its Swiss portfolio includes the antiepileptic medication Ontozry (cenobamate).
Who are Arvelle Therapeutics's investors?
Arvelle Therapeutics's investors include Andera Partners, F-Prime Capital, H.I.G. Capital, H.I.G. HealthBridge Partners.
Where is Arvelle Therapeutics headquartered?
Arvelle Therapeutics is headquartered in Zug, CH.